Moderna (Germany) Top Insiders
| 0QF Stock | EUR 44.24 1.45 3.39% |
Moderna employs about 4.7 K people. The company is managed by 30 executives with a total tenure of roughly 149 years, averaging almost 4.0 years of service per executive, having 156.67 employees per reported executive. Examination of Moderna's management performance can provide insight into the company performance.
| Stphane MBA CEO CEO Director |
| Stephane Bancel CEO Chief Executive Officer, Director |
Moderna |
Moderna Management Team Effectiveness
The company has return on total asset (ROA) of (0.1451) % which means that it has lost $0.1451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2887) %, meaning that it generated substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The Moderna's current Return On Tangible Assets is estimated to increase to -0.22. The Moderna's current Return On Capital Employed is estimated to increase to -0.28. At this time, Moderna's Debt To Assets are most likely to increase slightly in the upcoming years. The Moderna's current Asset Turnover is estimated to increase to 0.22, while Non Current Assets Total are projected to decrease to roughly 4.6 B.The Moderna's current Net Income Applicable To Common Shares is estimated to increase to about 10.1 B, while Common Stock Shares Outstanding is projected to decrease to roughly 404.9 M. Moderna maintains a total of 390.73 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Moderna in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Moderna, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Moderna Workforce Comparison
Moderna is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2.23 Million. Moderna adds roughly 4,700 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (1.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.26. Moderna Benchmark Summation
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Lowest value over a specified period line plots minimum value of Moderna price series.
Moderna Notable Stakeholders
A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Stphane MBA | CEO Director | Profile | |
| Stephane Bancel | Chief Executive Officer, Director | Profile | |
| Stphane Bancel | CEO Director | Profile | |
| David Meline | Chief Financial Officer | Profile | |
| Francois Nader | Non-Executive Independent Director | Profile | |
| Marcello Damiani | Chief Digital and Operational Excellence Officer | Profile | |
| Dave Johnson | Chief Officer | Profile | |
| Lavina CFA | Senior Relations | Profile | |
| Noubar Afeyan | Non-Executive Independent Chairman of the Board, Co-Founder | Profile | |
| Ray Jordan | Chief Corporate Affairs Officer | Profile | |
| Jerh Collins | Chief Officer | Profile | |
| Juan Andres | Chief Technical Operations and Quality Officer | Profile | |
| Charbel MPH | Senior Science | Profile | |
| Israel Ruiz | Non-Executive Independent Director | Profile | |
| Shannon Klinger | Chief Sec | Profile | |
| James Mock | Chief Officer | Profile | |
| Lori Henderson | General Counsel, Company Secretary | Profile | |
| Tal Zaks | Chief Medical Officer | Profile | |
| John Reynders | Chief Officer | Profile | |
| Paul Sagan | Non-Executive Independent Director | Profile | |
| Melissa Moore | Chief Board | Profile | |
| Elizabeth Tallett | Director | Profile | |
| Stephen Hoge | President | Profile | |
| Stephen Berenson | Non-Executive Independent Director | Profile | |
| Stephen MD | President | Profile | |
| Shannon JD | Chief Secretary | Profile | |
| Robert Langer | Non-Executive Independent Director | Profile | |
| Tracey Franklin | Chief Human Resource Officer | Profile | |
| MBA OBE | Chief Officer | Profile | |
| MD FAAP | Chief Officer | Profile |
About Moderna Management Performance
The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.22) | |
| Return On Capital Employed | (0.30) | (0.28) | |
| Return On Assets | (0.23) | (0.22) | |
| Return On Equity | (0.33) | (0.31) |
Moderna Workforce Analysis
Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.Moderna Manpower Efficiency
Return on Moderna Manpower
| Revenue Per Employee | 680.6K | |
| Revenue Per Executive | 106.6M | |
| Net Loss Per Employee | 757.7K | |
| Net Loss Per Executive | 118.7M | |
| Working Capital Per Employee | 1.3M | |
| Working Capital Per Executive | 196.4M |
Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |